April 06, 2020
A New York federal judge granted certification Monday to a class of thousands of Mylan NV investors who say the pharmaceutical giant committed securities fraud by misleading them about how it was allegedly overcharging Medicaid for EpiPen purchases and engaging in other anti-competitive conduct.
March 29, 2019
After trimming some claims and statements, a New York federal judge said Friday that he would not dismiss all of the new claims in an amended investor suit against Mylan NV over allegedly anti-competitive behavior involving its EpiPen epinephrine auto-injector.
September 06, 2018
Investors in Mylan NV fired back at what they called a scattershot motion to dismiss their amended claims about alleged anti-competitive behavior involving the drugmaker's EpiPen epinephrine auto-injector, saying their latest allegations are "well-pleaded and damning."
August 07, 2018
Drugmaker Mylan NV on Monday urged a New York federal court to dismiss investors' amended allegations about alleged anti-competitive behavior involving its EpiPen epinephrine autoinjector, saying the bulk of the allegations were simply copied from other complaints.
March 29, 2018
EpiPen maker Mylan NV must face a trimmed-down proposed securities fraud class action accusing it of misleading investors about how it was allegedly overcharging Medicaid for EpiPen purchases and engaging in other anti-competitive conduct, a New York federal judge ruled Wednesday.
August 11, 2017
Investors in EpiPen maker Mylan NV have pushed back against the pharmaceutical company's bid to toss their securities fraud proposed class action, telling a New York federal court that Mylan hasn't even challenged two of the categories of misstatements alleged in their complaint.
May 31, 2017
EpiPen maker Mylan NV asked a New York federal judge on Tuesday to throw out a shareholder suit that accuses it of securities fraud, saying the investors' references to other investigations and lawsuits that have hurt its stock price in recent years don't amount to proof of wrongdoing.
October 11, 2016
The damage Mylan is facing for underpaying Medicaid rebates by misclassifying the EpiPen as a generic drug hasn't ended with Friday's $465 million Justice Department settlement, as the U.S. Securities and Exchange Commission and investors have respectively launched an investigation and a potential class action in New York.